Mirum Pharmaceuticals, Inc. (FRA:08D)

Market Cap	4.63B +130.4%
Revenue (ttm)	444.00M +54.7%
Net Income	-19.90M
EPS	-0.40
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	75.00
Previous Close	76.50
Day's Range	74.50 - 76.50
52-Week Range	32.40 - 92.50
Beta	n/a
RSI	47.23
Earnings Date	May 4, 2026

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2018
• Employees: 371
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 08D

Financial Performance

In 2025, Mirum Pharmaceuticals's revenue was $521.31 million, an increase of 54.74% compared to the previous year's $336.89 million. Losses were -$23.36 million, -73.43% less than in 2024.

Financial numbers in USD